Biomarkers of endothelial dysfunction after operations using homografts for lower limb arterial reconstruction (a pilot study)
AbstractObjective. The purpose of this study was to test a hypothesis about the diagnostic significance of changes in the levels of endothelial dysfunction markers for predicting the progression of atherosclerosis after using homografts in reconstruction of lower limb arteries.
Patients and methods. The study was conducted in accordance with the GCP (Good Clinical Practice) standards and principles of the Declaration of Helsinki. The protocol was approved by the Local Ethics Committee № 4 dated November 9, 2021. The study was registered on the platform ClinicalTrials.gov (identifier NCT05455138), being an independent, prospective, clinical, uncontrolled trial. The first “pilot” data were obtained in treating ten patients with stage III–IV obliterating atherosclerosis of lower limb arteries (according to the classification of A.V. Pokrovsky-Fontaine). The patients were operated on at the Department of Vascular Surgery of the Ryazan Regional Clinical Hospital. The inclusion criteria were as follows: use of a homograft (irrespective of the type) as a material for reconstruction of major arteries, the presence of atherosclerosis of the latter, males of females over 40 years of age, with the following exclusion criteria: another-etiology chronic lower limb ischemia (Buerger’s disease, aortoarteritis, etc.), active cancer or a period of remission less than 5 years, patients’ refusal to participate in clinical research.
The study enrolled a total of ten patients (7 men and 3 women), average age 62.6 (42–78) years. Arterial and venous homografts were used as a material for reconstructive and restorative intervention in all patients. We used 5 alloarteries and 5 alloveins. Blood serum levels of endothelin-1 (ET-1), interleukin-6 (IL-6), endothelial nitric oxide synthase (eNOS) and prostacyclin (PGI2) were measured at various time points (the day before surgery, after 7 days, 1 month, 3 months, 6 months, 1 year). The overall duration of postoperative follow-up amounted to 1 year.
Results. The obtained findings demonstrated an increase in the ET-1 level by 75% on POD 7 (p=0.004) and by 73% (p=0.05) at 3 months versus the baseline values, a 107% increase of the IL-6 level at 1 year (p=0.001), with a three-fold increase of the eNOS level at 3 months (p=0.006) and also a three-fold increase at 1 year (p=0.001). The PGI2 level in blood serum increased multiply at 1 year after surgery vs. the baseline level (p=0.024). Nine patients were discharged with saved extremities and relief of critical ischemia. The progression of atherosclerosis was observed in four patients. There were 2 thromboses of homografts in the position below the knee-joint fissure without development of acute limb ischemia. Two patients were found to have the progression of atherosclerosis on the contralateral extremity – a decrease of the pain-free walking distance to 200 m in one patient, and the appearance of rest pain in the other, thus requiring elective endovascular intervention. These patients were found to have a two-fold increase in the ET-1 (p=0.004) and IL-6 (p=0.02) levels at 1 year compared with those in patients without progression of atherosclerosis.
Conclusion. The levels of endothelin-1, interleukin-6, endothelial nitric oxide synthase and prostacyclin can be used for predicting the progression of atherosclerosis after operations using homografts. Elevated levels of ET-1 and IL-6 are predictors of thrombotic complications. The values of endothelial nitric oxide synthase and prostacyclin also increase in the remote postoperative period. Given the conclusive results of our research, further studies are warranted to confirm our findings in larger cohorts.
Funding. The study had no financial support.
Conflict of interest. The authors declare no conflicts of interest.
Authors’ contribution. Study conception and design – Kalinin R.E., Suchkov I.A.; development of methodology – Suchkov I.A., Karpov V.V.; data collection and handling – Karpov V.V., Nikiforov A.А.; surgical intervention – Karpov V.V., Egorov A.A.; draft manuscript preparation – Karpov V.V., Suchkov I.A..; manuscript revision – Suchkov I.A., Kalinin R.E., Klimentova E.A.
For citation: Kalinin R.E., Suchkov I.A., Karpov V.V., Klimentova E.A., Egorov A.A., Nikiforov A.А. Biomarkers of endothelial dysfunction after operations using homografts for lower limb arterial reconstruction (a pilot study). Angiology and Vascular Surgery. Journal named after Academician A.V. Pokrovsky. 2024; 30 (1): 138–45. DOI: https://doi.org/10.33029/1027-6661-2024-30-1-138-145
Keywords: lower extremity arterial disease; homograft; endothelin-1; interleukin-6; endothelial nitric oxide synthase; prostacyclin
References
1. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473 (7347): 317–325. DOI: https://doi.org/10.1038/nature10146
2. Fowkes F.G.R., Rudan D., Rudan I., et al. Comparison of Global Estimates of Prevalence and Risk Factors for Peripheral Artery Disease in 2000 and 2010: A Systematic Review and Analysis. Lancet. 2013; 382 (9901): 1329–1340. DOI: https://doi.org/10.1016/S0140-6736(13)61249-0
3. Song P., Rudan D., Zhu Y.I., et al. Global, Regional, and National Prevalence and Risk Factors for Peripheral Artery Disease in 2015: An Updated Systematic Review and Analysis. Lancet Global Health. 2019; 7 (8): e1020–e1030. DOI: https://doi.org/10.1016/S2214-109X(19)30255-4
4. Pokrovskij A.V., Jahontov D.I. Role of Venous Cuff in Femoral-Tibial Bypass Surgery. Bulletin of Pirogov National Medical & Surgical Center. 2013; 8 (4): 18–24. (in Russian)
5. Moreira C., Leung A., Farber A., et al. Alternative conduit for infrageniculate bypass in patients with critical limb ischemia. Journal of Vascular Surgery. 2016; 64 (1): 131–139.e1. DOI: https://doi.org/10.1016/j.jvs.2016.01.042
6. Albers M., Battistella V.M., Romiti M., et al. Meta-analysis of polytetrafluoroethylene bypass grafts to infrapop-liteal arteries. Journal of Vascular Surgery. 2003; 37 (6): 1263–1269. DOI: https://doi.org/10.1016/s0741-5214(02)75332-9
7. Pokrovsky A.V., Dan V.N., Chupin A.V., et al. The use of biological grafts in the femoral-popliteal-tibial position. Angiology and Vascular Surgery. 1996; 2 (3): 91–100. (in Russian)
8. Barbarash L.S., Ivanov S.V., Zhuravleva I.Yu., et al. 12 years of experience in using bioprostheses to replace the infrainguinal arteries. Angiology and Vascular Surgery. 2006; 12 (3): 91–97. (in Russian)
9. Tishchenko I.S., Zolkin V.N., Maksimov N.V., et al. Two-year results of infrainguinal reconstructions using autovenous shunts and xenografts. Angiology and Vascular Surgery. 2016; 22 (4): 130–135. (in Russian)
10. Mezhdunarodnye sosudistye rekomendatsii po lecheniyu khronicheskoy ishemii, ugrozhayushchey poterey konechnosti. Moskva. 2019; 160. (in Russian)
11. Munjal A., Khandia R. Atherosclerosis: orchestrating cells and biomolecules involved in its activation and inhibition. Advances in Protein Chemistry and Structural Biology. 2020; 120: 85–122. DOI: https://doi.org/10.1016/bs.apcsb.2019.11.002
12. Igari K., Kudo T., Toyofuku Y. Inoue Endothelial Dysfunction of Patients with Peripheral Arterial Disease Measured by Peripheral Arterial Tonometry. International Journal of Vascular Medicine. 2016; 2016: 3805380. DOI: https://doi.org/10.1155/2016/3805380
13. Saenz-Pipaon G., Martinez-Aguilar E., Orbe J., et al. The Role of Circulating Biomarkers in Peripheral Arterial Disease. International Journal of Molecular Sciences. 2021; 22 (7): 3601. DOI: https://doi.org/10.3390/ijms22073601
14. Erzen B., Sabovic M., Sebestjen M., et al. Interleukin-6 correlates with endothelial dysfunction in young post-myocardial infarction patients. Cardiology. 2007; 107 (2): 111–116. DOI: https://doi.org/10.1159/000094588
15. Hong F.F., Liang X.Y., Liu W., et al. Roles of eNOS in atherosclerosis treatment. Inflammation Research. 2019; 68 (6): 429–441. DOI: https://doi.org/10.1007/s00011-019-01229-9
16. Arehart E., Gleim S., Kasza Z., et al. Prostacyclin, atherothrombosis, and cardiovascular disease. Current Medicinal Chemistry. 2007; 14 (20): 2161–2169. DOI: https://doi.org/10.2174/092986707781389637
17. Kalinin R.E., Suchkov I.A., Karpov V.V., et al. The First Experience of Using Allografts in Surgery of Main Arteries of Lower Limbs. Russian Sklifosovsky Journal “Emergency Medical Care”. 2020; 9 (3): 442–448. DOI: https://doi.org/10.23934/2223-9022-2020-9-3-442-448 (in Russian)
18. Kalinin R.E., Solanik N.A., Suchkov I.A., et al. The place of arterial allograft in reconstructive surgery of the main arteries of the lower extremities. Pirogov Russian Journal of Surgery. 2020; 9: 69–74. DOI: https://doi.org/10.17116/hirurgia202009169 (in Russian)
19. Natsional’nye rekomendatsii po diagnostike i lecheniyu zabolevaniy arteriy nizhnikh konechnostey. Moskva. 2019; 89. (in Russian)
20. Porsheneva E.V., Kalinin R.E., Nikiforova L.V., et al. Effectiveness of cilostazol in prevention of restenosis after endovascular reconstructive procedures on the lower extremity arteries. Angiology and Vascular Surgery. 2022; 28 (3): 23–31. DOI: https://doi.org/10.33029/1027-6661-2022-28-3-23-31 (in Russian)
21. Hiemann N.E., Meyer R., Wellnhofer E., et al. Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation. 2012; 94 (9): 919–924. DOI: https://doi.org/10.1097/TP.0b013e3182692ad2
22. Simeone S.M., Li M.W., Paradis P., Schiffrin E.L. Vascular gene expression in mice overexpressing human endothelin-1 targeted to the endothelium. Physiological Genomics. 2011; 43 (3): 148–160. DOI: https://doi.org/10.1152/physiolgenomics.00218.2009
23. Wagrowska-Danilewicz M., Danilewicz M. Immunohistochemical study of endothelin-1 (ET-1) in human acute renal allograft rejection. Polish Journal of Pathology. 2003; 54 (2): 95–100.
24. Hartman J., Frishman W.H. Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy. Cardiology in Review. 2014; 22 (3): 147–151. DOI: https://doi.org/10.1097/crd.0000000000000021
25. Marsden P.A., Schappert C.T., Chen H.S., et al. Molecular cloning and characterization of human nitric oxide endothelial synthase. FEBS Letters. 307 (3): 287–293. DOI: https://doi.org/10.1016/0014-5793(92)80697-F
26. Qian J., Fulton D. Post-translational regulation of endothelial nitric oxide synthase in vascular endothelium. Frontiers in Physiology. 2013; 4: 347. DOI: https://doi.org/10.3389/fphys.2013.00347
27. Zhang B., Liu Q.-H., Zhou C.-J., et al. Protective effect of eNOS overexpression against ischemia/reperfusion injury in small-for-size liver transplantation. Experimental and Therapeutic Medicine. 2016; 12 (5): 3181–3188. DOI: https://doi.org/10.3892/etm.2016.3762
28. Porsheneva E.V., Nikiforova L.V., Povarov V.O. Effectiveness of Cilostazol in Patients with Intermittent Claudication. Science of the young (Eruditio Juvenium). 2022; 10 (2): 175–186. DOI: https://doi.org/10.23888/HMJ2022102175-186
29. Lewis P.J., Dollery C.T. Clinical pharmacology and potential of prostacyclin. British Medical Bulletin. 1983; 39 (3): 281–284. DOI: https://doi.org/10.1093/oxfordjournals.bmb.a071834
30. Kalinin R.E., Suchkov I.A., Porsheneva E.V., Krylov A. A. Prospects of using cilostazol in combined treatment of patients with obliterating atherosclerosis of lower limb arteries. Science of the young (Eruditio Juvenium). 2021; 9 (4): 619–630. DOI: https://doi.org/10.23888/HMJ202194619-630 (in Russian)
All articles in our journal are distributed under the CC BY-NC-ND 4.0 (Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International)
п?? GEOTAR-Media Publishing Group. The use of textual and illustrative content from this publication for the training of any artificial intelligence systems п?? including machine learning models and neural networks п?? is strictly prohibited without the prior written consent of the copyright holder.